alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Materials Not Included in Airworthiness Directive (AD) Docket

Docket Number: FAA- 2009-1213 Directorate Identifier: 2009NM097 AD

MD80-57A242 --- 5/8/09

Name/Description of Item(s) Not Included in FDMS Docket and Maintained inthe Supplemental AD Docket
MAY BEVIEWED AT: Federal Aviation Administration Transport Airplane Directorate Rules Docket 1601 LindAve. SW., Renton, WA 98057 425.227.1221 DURING THE HOURS OF: 9a.m. and 3p.m., Monday through Friday, except Federal holidays. Form Date: 03/05/2008
# Materials Not Included in **Airworthiness Directive (AD) Docket**

Docket Number: F AA - 2015 - 0822 Directorate Identifier: 2014NM210AD

SB 670BA - 35 - 013, Rev A --- 9/23/13 SB 670BA - 35 - 013 --- 5/21/13

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the Supplemental AD Docket 

### MA **Y BE VIEWED AT:** Federal Avi ation Administration

Transport Airplane Directorate Rules Docket 1601 Lind Ave. SW., Renton, WA 98057 425.227.1221 **DURING THE HOURS OF:** 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Form Date: 0 3/05/2008
#### § 589.1001 Propylene glycol in or on cat food.

The Food and Drug Administration has determined that propylene glycol in or on cat food has not been shown by adequate scientific data to be safe for use. Use of propylene glycol in or on cat food causes the feed to be adulterated and in violation of the Federal Food, Drug, and Cosmetic Act (the act), in the absence of a regulation providing for its safe use as a food additive under section 409 of the act, unless it is subject to an effective notice of claimed investigational exemption for a food additive under § 570.17 of this chapter, or unless the substance is intended for use as a new animal drug and is subject to an approved application under section 512 of the act or an effective notice of claimed investigational exemption for a new animal drug under part 511 of this chapter.

[61 FR 19544, May 2, 1996]
§ 740.2 Conspicuousness of warning statements. ( a ) A warning statement shall appear on the label prominently and conspicuously as compared to other words, statements, designs, or devices and in bold type on contrasting background to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use, but in no case may the letters and/or numbers be less than 1 ⁄ 16 inch in height, unless an exemption pursuant to paragraph (b) of this section is established.
( b ) If the label of any cosmetic package is too small to accommodate the information as required by this section, the Commissioner may establish by regulation an acceptable alternative method, e.g., type size smaller than 1 ⁄ 16 inch in height. A petition requesting such a regulation, as an amendment to this section, shall be submitted to the Dockets Management Staff in the form established in part 10 of this chapter.
[40 FR 8917, Mar. 3, 1975, as amended at 42 FR 15676, Mar. 22, 1977; 69 FR 13717, Mar. 24, 2004; 88 FR 45067, July 14, 2023]
* Circuit Judge of the Ninth Circuit, sitting by designation.

** Pursuant to 5 T H C IR

. R. 47.5, the court has determined that this opinion sh ould not be

published and is not precedent except under the limit ed circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals

Fifth Circuit



## FILED

May 30, 2003

Charles R. Fulbruge III

Clerk UNITED STATES COURT OF APPEALS

FIFTH CIRCUIT

____________

No. 02-60572

____________

MISSISSIPPI TRUCKING ASSOCIATION, INC.; MISSISSIPPI

TRUCKING ASSOCIATION MANAGEMENT SERVICES

INCORPORATED EMPLOYEE WELFARE BENEFIT PLAN,

Plaintiffs-Appellants,

versus

F. A. RICHARD & ASSOCIATES, INC., doing business as Fara

Benefit Services; LEON GOLEMI,

Defendants-Appellees.

Appeal from the United States District Court

For the Southern District of Mississippi

No. 3:01-CV-369-BN

Before DAVIS, CYNTHIA HOLCOMB HALL * and EMILIO M. GARZA, Circuit Judges.

PER CURIAM: **

Mississippi Trucking Association, Inc. and Mississippi Tru c king Association Management-2-

Services, Inc. Employee Welfare Benefit Plan (collectively, “MTA”) appeal the district court’s grant

of summary judgment in favor of F.A. Richard & Associates, Inc., doing business as FARA Benefit

Services, and its Director, Leon Golemi (collectively, “FARA”). This dispute arises out of FARA’s

role in establishing a partially self-funded employ ee healt h benefits plan for the use of MTA’s

members. MTA claims that FARA represented that MTA’s exposure under the plan would be limited

to $2 00,000, whereas the pl an has to date cost MTA at l east $585,917.90. On appeal , MTA

contends that the district court erred in concluding that no genuine issues of material fact existed as

to its negligence, promissory estoppel and fraud claims.

We have read the briefs, heard the arguments of counsel, and consulted the pertinent portions

of the record. On the basis of the record, the exhibits and the applicable case law, we find no

reversible error. Accordingly, we AFFIRM essentially for the reasons given by the district court.
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                     the Securities and Exchange Act of 1934

       Date of Report (Date of earliest event reported) November 30, 2001

                            R-TEC TECHNOLOGIES, INC.
             (Exact name of Registrant as specified in its charter)

   New Jersey                      333-72405                     22-3615979
 State or Other                (Commission File                 IRS Employer
Jurisdiction of                     Number)                Identification Number
 Incorporation)

                   37 Ironia Road, Flanders, New Jersey 07836
               (Address of principal executive offices)(Zip Code)

                                 (973) 252-5233
               Registrant's telephone number, including area code)

<PAGE>

Item 5. Other Events

On November 30, 2001 R-TEC Technologies,  Inc. (R-Tec) entered into an agreement
with three individuals,  Maj. Gen. William F. Ward (ret.),  Louis L. Levine, and
Daniel Stack to become  consultants to the Company and to be the initial members
of a Board of  Advisors.  The  consultants  were  retained  to  assist  R-TEC in
achieving its goals and objectives by, among other things,  introducing R-TEC to
private and governmental entities.

Each  individual  shall receive 102,640 shares of R-TEC's common stock for which
R-TEC has agreed to file a registration  statement within 180 days from November
30, 2001. In addition,  the consultants will collectively receive 15% of the net
profit on all sales of R-TEC's  C-BAND  products and services and C-BAND related
products and services.

Exhibit
Number   Description

1        Agreement dated November 30, 2001 by and among R-TEC Technologies, Inc.
         and Maj.  Gen.  William F. Ward  (ret.),  Louis L.  Levine,  and Daniel
         Stack.

<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                       R-TEC TECHNOLOGIES, INC.

                                       By: /s/ Philip Lacqua
                                           -------------------------------------
                                               Philip Lacqua
                                               Chief Executive Officer

Dated: December 10, 2001
I 

118TH CONGRESS 

2D SESSION H. R. 7397 

To amend title XVIII of the Social Security Act to establish a definition 

of essential health system in statute. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Mrs. TRAHAN (for herself and Mr. VALADAO) introduced the following bill; 

which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of 

such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to establish 

a definition of essential health system in statute. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ESTABLISHING A DEFINITION OF ESSENTIAL 

4 HEALTH SYSTEM IN STATUTE. 

5 Section 1861 of the Social Security Act (42 U.S.C. 

6 1395x) is amended by adding at the end the following new 

7 subsection: 

8 ‘‘(nnn) ESSENTIAL HEALTH SYSTEM.—The term ‘es9 sential health system’ means a hospital— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7397 IH

1 ‘‘(1) that is a subsection (d) hospital (as de2 fined in section 1886(d)(1)(B)); 

3 ‘‘(2) that is a non-Federal governmental or pri4 vate nonprofit hospital; and 

5 ‘‘(3) that— 

6 ‘‘(A) meets the requirements of a Medicaid 

7 deemed disproportionate share hospital (as de8 scribed in section 1923(b)(1)); 

9 ‘‘(B) has a Medicare disproportionate pa10 tient percentage of at least 35 percent (as de11 fined in section 1886(d)(5)(F)(vi)); or 

12 ‘‘(C) has a Medicare disproportionate 

13 share hospital uncompensated care payment 

14 factor of 0.0005 or more, (as defined in section 

15 1886(r)(2)(C)).’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1452 Manganese gluconate. ( a ) Manganese gluconate (C12H22MnO14·2H2O, CAS Reg. No. 648-0953-0998) is a slightly pink colored powder. It is obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 186, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient is used in the following foods at levels not to exceed current good manufacturing practice: baked goods as defined in § 170.3(n)(1) of this chapter; nonalcoholic beverages as defined in § 170.3(n)(3) of this chapter; dairy product analogs as defined in § 170.3(n)(10) of this chapter; fish products as defined in § 170.3(n)(13) of this chapter; meat products as defined in § 170.3(n)(29) of this chapter; milk products as defined in § 170.3(n)(31) of this chapter; and poultry products as defined in § 170.3(n)(34) of this chapter. The ingredient may be used in infant formulas in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) or with regulations promulgated under section 412(a)(2) of the act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[50 FR 19166, May 7, 1985]
| (1)   | The      Report fully complies with the requirements of Section 13(a) or 15(d) of      the Securities Exchange Act of 1934;and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The      information contained in the Report fairly presents, in all material      respects, the financial condition and results of operations of the      Company. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                  | CEC Entertainment,      Inc. |                                       |
|-----------------------|------------------------------|--------------------------------------------|
|                  |                         |                                       |   |
| October      29, 2009 | By:                          | /s/ Michael      H. Magusiak          |   |
|                  |                         | Michael      H. Magusiak                   |   |
|                  |                         | President      and Chief Executive Officer |   |
|                  |                         |                                       |   |
SHERIDAN HEALTHCARE, INC.
                                  EXHIBIT 21.1
                    Schedule of Subsidiaries and Affiliates
                           (As of December 31, 1997)

I.  SUBSIDIARIES:

    A.   SHERIDAN HEALTHCORP, INC., a Florida corporation

         SUBSIDIARIES:

         1.  SHERIDAN HEALTHCARE OF WEST FLORIDA, INC., a Florida corporation
             (f/k/a AMSA, Inc.)

         2.  PRIMEDICA HEALTHCARE, INC., a Florida corporation

    B.   MEDISERV, INC., a Florida corporation (f/k/a Group Practice Management,
         Inc.)

    C.   SHERIDAN CHILDREN'S HEALTHCARE SERVICES, INC., a Florida corporation
         (f/k/a Neonatology Certified, Inc.)

         SUBSIDIARY:

          1.  SHERIDAN CHILDREN'S HEALTHCARE SERVICES OF WEST VIRGINIA, INC.,
              a West Virginia corporation

     D.  CHILDREN'S HOSPITAL SERVICES, INC., a Florida corporation

     E.  SHERIDAN  HEALTHCARE  OB/GYN,   INC.,  a  Florida  corporation  (f/k/a
         Sheridan Healthcare of Puerto Rico, Inc.)

     F.  SHERIDAN FINANCE CORP., a Delaware corporation

II.  AFFILIATES:

     A.  SHERIDAN MEDICAL HEALTHCORP, P.C., a New York professional corporation

         SUBSIDIARY:

         1. SHERIDAN STC CORP., a Delaware corporation

     B.  SHERIDAN HEALTHCARE OF TEXAS, P.A., a Texas professional association

     C.  SHERIDAN HEALTHCARE OF CALIFORNIA MEDICAL GROUP, INC.,
         a California professional corporation

     D.  SHERIDAN CHILDREN'S HEALTHCARE SERVICES OF PENNSYLVANIA, P.C.,
         a Pennsylvania professional corporation
<PAGE>

III. OTHER MANAGED AFFILIATES:

     A.  WEST BROWARD OB/GYN, P.A., a Florida professional association

     B.  BECERRA & AUGUSTINO, M.D., INC., a Florida corporation

     C.  CASTILLO-PLAZA & ASSOCIATES, M.D., INC., a Florida corporation

     D.  DRS. GRABIOS, FIRESTONE, HALFON & LEBOW, P.A., a Florida
         professional association

     E.  WOMAN TO WOMAN OBSTETRICS & GYNECOLOGY, P.A., a Florida
         professional association

     F.  FREDERICK N. HERMAN, M.D., INC., a Florida corporation
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Environmental Protection Agency

          - [ER-FRL-8988-5]

*Responsible Agency:*                     Office of Federal Activities, General Information (202) 564-1399 or                     *http://www.epa.gov/​compliance/​nepa/​.*

Weekly receipt of Environmental Impact Statements Filed 02/23/2010 Through 02/23/2010 Pursuant to 40 CFR 1506.9;

### Notice

                    In accordance with Section 309(a) of the Clean Air Act, EPA is required to make its comments on EISs issued by other Federal agencies public. Historically, EPA has met this mandate by publishing weekly notices of availability of EPA comments, which includes a brief summary of EPA's comment letters, in the Federal Register. Since February 2008, EPA has been including its comment letters on EISs on its Web site at:                     *http://www.epa.gov/​compliance/​nepa/​eisdata.html.*                     Including the entire EIS comment letters on the Web site satisfies the Section 309(a) requirement to make EPA's comments on EISs available to the public. Accordingly, after March 31, 2010, EPA will discontinue the publication of this notice of availability of EPA comments in the                     **Federal Register**                    .                

*EIS No. 20100057, Final EIS, NHTSA, 00,*                     Corporate Average Fuel Economy (CAFE) Standards Passenger Car and Light Trucks Model Years 2012-2016, To Reduce National Energy Consumption by Increasing the Fuel Economy of Passenger Car and Light Trucks sold in the United States, Implementation, Wait Period Ends: 04/01/2010, Contact: Angel Jackson 202-366-0154.                

Dated: February 26, 2010.

Robert W. Hargrove,

Director, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 2010-4389 Filed 3-2-10; 8:45 am]

BILLING CODE 6560-50-P
§ 524.1044d Gentamicin and betamethasone ointment. ( a ) *Specifications.* Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount* — ( i ) *Otitis externa.* Instill 3 to 8 drops into the ear canal twice daily for 7 days.
( ii ) *Infected superficial lesions.* Apply to cover the treatment area twice daily for 7 to 14 days.
( 2 ) *Indications for use.* For the treatment of acute and chronic otitis externa and infected superficial lesions caused by bacteria sensitive to gentamicin.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[47 FR 26378, June 18, 1982, as amended at 52 FR 7832, Mar. 13, 1987; 79 FR 10969, Feb. 27, 2014]
§ 510.213 Administrative stay of action. ( a ) The Commissioner may at any time, on his or her own initiative or on the request of an interested person under part 10 of this chapter, stay or extend the effective date of a decision to establish, not establish, amend, or revoke an import tolerance.
( b ) A request for stay must be submitted in accordance with § 10.20 of this chapter and in the form specified in § 10.35 of this chapter no later than 30 days after public notification of the decision involved. The Commissioner may, for good cause, permit a petition to be filed more than 30 days after public notification of the decision.
### T E X A S C O U R T O F A P P E A L S , T H I R D D I S T R I C T , A T A U S T I N

NO. 03-09-00500- CR

Charles Ham ilton Jr., Appellan t

v. The State of Texas, App ellee

F ROM TH E DISTRI CT COURT O F TRAVIS CO UNTY, 299 TH JUDICI AL DISTRICT NO. D-1 -DC- 09- 9040 60, H ONO RAB LE CHARLES F . B AIRD, JUDGE P RESIDING

M E M O R A N D U M O P I N I O N A j ury found appellant Charles Hamilton J r. guilty of burglar y of a habitation with intent to commit theft. See Tex. Pen al C o d e An n . § 30.02 (West 2003). The court assessed punishment, enhanc ed by two previous fe lony

convictions, at imprisonment for life. Appellant’s court-a

ppointed attorney has filed a motion to withdraw supported by a brief concluding that the appea l is frivolous and without merit. The brief meets the require ments of Anders v. Calif

ornia , 386 U.S. 73 8 , 7 4 4 (1967), by prese nting a profe ssional evalua tion of the

rec ord demonstrating why there are no arg uable g rounds to be advanc ed. See also Penson v. Ohio , 488 U.S. 75 (1 9 8 8 ); Hi

g h v. State , 573 S.W .2d 807 (Tex. Crim. App. 1978); Currie v. State , 516 S.W .2d 684 (Tex. Crim. App. 1974); Jack son v. State , 485 S.W .2d 553 (Tex. Crim. App. 1972); Gainous v. State , 436 S.W .2d 137 (Tex. Crim. App. 1969). Appellant rec eived a copy of counsel’sbrief and was advised of his rig ht to examine the appellate rec ord and to file a pro se brief. See

Anders , 386 U.S. at 744. No pro se br ief ha s been f iled. We have revie wed the rec ord and find no reve rsible err or. See Garner v. State , 300 S.W .3d 763, 766 (Tex. Crim. App. 2009); Bledsoe v. State , 178 S.W .3d 824, 826-27 (Tex. Crim. App. 2005). We ag ree with counsel that t h e appea l is frivolous. Counsel’s motion to withdraw is gr anted. The judg ment of convic tion is affirmed.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ J an P. Patterson, J ustice Be fore J ustices Patterson, Pury ear and He nson Affir med Filed: Jul y

15, 2010 Do Not Publish

2
EXHIBIT 32
----------




                         CERTIFICATIONS OF
        CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                PURSUANT TO 18 U.S.C. SECTION 1350,
             AS ADOPTED PURSUANT TO SECTION 906 OF THE
                    SARBANES-OXLEY ACT OF 2002
        ---------------------------------------------------



     The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ALP Liquidating Trust.




                                     /s/   Gary Nickele
                                     ------------------------------
                                     Gary Nickele
                                     Chief Executive Officer




                                     /s/   Gailen J. Hull
                                     ------------------------------
                                     Gailen J. Hull
                                     Chief Financial Officer and
                                     Principal Accounting Officer
§ 524.1610 Orbifloxacin, mometasone furoate monohydrate, and posaconazole suspension. ( a ) *Specifications.* Each gram of suspension contains 10 milligrams (mg) orbifloxacin, mometasone furoate monohydrate equivalent to 1 mg mometasone furoate, and 1 mg posaconazole.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* For dogs weighing less than 30 lbs. instill 4 drops once daily into the ear canal. For dogs weighing 30 lbs. or more, instill 8 drops into the ear canal. Therapy should continue for 7 consecutive days.
( 2 ) *Indications for use.* For the treatment of otitis externa associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (coagulase-positive staphylococci, *Pseudomonas aeruginosa*, and *Enterococcus faecalis*).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[75 FR 16346, Apr. 1, 2010]